Key result
No clinical data is present in this document, which is a copyright transfer and author contribution form.
Newer oral anticoagulants like dabigatran and rivaroxaban have predictable effects and short half-lives, potentially eliminating the need for bridging therapy during the perioperative period.
No clinical data available; leaves open whether NOACs eliminate perioperative bridging.
It is anticipated that an increasing number of patients undergoing surgical procedures will be taking new anticoagulants and antiaggregants. Currently, only a small amount of data (which were derived from subgroup analyses of undedicated studies) exist regarding the optimal strategy in these patients. Clinical studies are urgently required to establish safe surgical procedures for this high risk patient population. Unlike warfarin, dabigatran and rivaroxaban have predictable and consistent anticoagulant effects with a rapid onset of action, short half-life, and consequently no need for routine laboratory testing. The pharmacologic profiles of these drugs represent an advantage for patients on chronic oral anticoagulant treatment who are undergoing invasive procedures. These drugs may minimize patient time spent without the antithrombotic effects of oral anticoagulants during the perioperative period, potentially eliminating the need for bridging therapy altogether.
No takes yet. Share an insight, caveat, or question.
Karadağ et al. (2012) studied this question. No clinical data is present in this document, which is a copyright transfer and author contribution form.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: